Zacks Investment Research cut shares of NxStage Medical, Inc. (NASDAQ:NXTM) from a hold rating to a sell rating in a report released on Tuesday morning.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

Other equities research analysts have also issued reports about the company. Canaccord Genuity lowered NxStage Medical from a buy rating to a hold rating and set a $30.00 price objective on the stock. in a research report on Monday, August 7th. BidaskClub cut NxStage Medical from a hold rating to a sell rating in a research note on Monday, July 31st. Craig Hallum cut NxStage Medical from a buy rating to a hold rating in a research note on Monday, August 7th. BTIG Research cut NxStage Medical from a buy rating to a neutral rating in a research note on Friday, August 11th. Finally, Stephens cut NxStage Medical from an overweight rating to an equal weight rating and lowered their target price for the company from $33.00 to $30.00 in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The company currently has a consensus rating of Hold and an average target price of $30.25.

Shares of NxStage Medical (NASDAQ NXTM) traded up $0.11 during mid-day trading on Tuesday, hitting $25.99. The stock had a trading volume of 275,240 shares, compared to its average volume of 569,230. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/18/nxstage-medical-inc-nxtm-lowered-to-sell-at-zacks-investment-research.html.

In other NxStage Medical news, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction on Monday, August 21st. The stock was sold at an average price of $29.22, for a total transaction of $125,646.00. Following the completion of the transaction, the senior vice president now owns 28,721 shares in the company, valued at $839,227.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,600 shares of company stock valued at $484,722. 4.70% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new position in NxStage Medical during the third quarter valued at $202,000. Quantitative Systematic Strategies LLC purchased a new position in NxStage Medical during the second quarter valued at $203,000. Amalgamated Bank raised its stake in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after buying an additional 553 shares during the last quarter. Athos Capital Ltd purchased a new position in NxStage Medical during the third quarter valued at $557,000. Finally, Suntrust Banks Inc. raised its stake in NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after buying an additional 209 shares during the last quarter. Institutional investors and hedge funds own 92.31% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.